Detection of enzymes for effective treatment of kidney cancer

According to a study published in the American Journal of Clinical Oncology, Duke Cancer Institute researchers have recently discovered a blood enzyme that may help determine effective treatments for kidney cancer. Best.

This enzyme is called LDH . So far, scientists have known that high levels of LDH are considered to be one of the risk factors for kidney cancer patients.

Scientists studied the data of 404 patients with kidney cancer, half of whom were treated with a standard drug Interferon Alpha and the rest were treated with Temsirolimus.

The results showed that LDH helps professionals, doctors determine the most appropriate treatment for each patient.

Scientists have found that the average survival rate of kidney cancer patients with high levels of LDH is 6.9 months when treated with Temsirolimus and 4.2 months when treated with Interferon Alpha.

The study also shows that there is almost no difference in survival time thanks to the two drugs for patients with low LDH levels.

According to one of the authors of this study, the detection of LDH enzyme will help guide patients with the best treatments. This is a great progress in the fight against the disease.